The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Cancer treatment cost in the United States: Has the burden shifted over time?
Abstract
BACKGROUND: There has not been a comprehensive analysis of how aggregate cancer costs have changed over time. The authors present 1) updated estimates of the prevalence and total cost of cancer for select payers and how these have changed over the past 2 decades; and 2) for each payer, the distribution of payments by type of service over time to assess whether there have been shifts in cancer treatment settings. METHODS: Pooled data from the 2001 through 2005 Medical Expenditure Panel Survey and the 1987 National Medical Care Expenditure Survey were used for the analysis. The authors used an econometric approach to estimate cancer‐attributable medical expenditures by payer and type of service. RESULTS: In 1987, the total medical cost of cancer (in 2007 US dollars) was $24.7 billion. Private payers financed the largest share of the total (42%), followed by Medicare (33%), out of pocket (17%), other public (7%), and Medicaid (1%). Between 1987 and the 2001 to 2005 period, the total medical cost of cancer increased to $48.1 billion. In 2001 to 2005, the shares of cancer costs were: private insurance (50%), Medicare (34%), out of pocket (8%), other public (5%), and Medicaid (3%). The share of total cancer costs that resulted from inpatient admissions fell from 64.4% in 1987 to 27.5% in 2001 to 2005. CONCLUSIONS: The authors identified 3 trends in the total costs of cancer: 1) the medical costs of cancer have nearly doubled; 2) cancer costs have shifted away from the inpatient setting; and 3) the share of these costs paid for by private insurance and Medicaid have increased. Cancer 2010. Published 2010 by American Cancer Society.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It was estimated that $74.9 billion of the health care costs in 2013 were for uncompensated care received by those without insurance.30”
From US Health Care Spending by Payer and Health Condition, 1996-2016 (2020) · cites this paper as [30]
Citations
Cites
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L. D., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,456
Estimating log models: to transform or not to transform?
Manning, W. G., & Mullahy, J. (2001) · Journal of Health Economics · doi:10.1016/s0167-6296(01)00086-8 · Cited by 1,790
Jemal, A., Thun, M. J., Ries, L. A. G., Howe, H. L., Weir, H. K., Ward, E., Wu, X., Eheman, C. R., Anderson, R. N., Ajani, U. A., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn389 · Cited by 961
Cost of Care for Elderly Cancer Patients in the United States
Yabroff, K. R., Lamont, E. B., Mariotto, A. B., Warren, J. L., Topor, M. A., Meekins, A., & Brown, M. L. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn103 · Cited by 700
The Price Tag on Progress — Chemotherapy for Colorectal Cancer
Schrag, D. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048143 · Cited by 437
Evaluation of Trends in the Cost of Initial Cancer Treatment
Warren, J. L., Yabroff, K. R., Meekins, A., Topor, M. A., Lamont, E. B., & Brown, M. L. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn175 · Cited by 388
Use of a Self-Report-Generated Charlson Comorbidity Index for Predicting Mortality
Chaudhry, S. I., Jin, L., & Meltzer, D. (2005) · Medical Care · doi:10.1097/01.mlr.0000163658.65008.ec · Cited by 368
The Medical Expenditure Panel Survey: a national health information resource.
(1996) · PubMed · Cited by 338
Patient Time Costs Associated With Cancer Care
Yabroff, K. R., Davis, W. W., Lamont, E. B., Fahey, A., Topor, M. A., Brown, M. L., & Warren, J. L. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk001 · Cited by 219
Risk Factors for Melanoma by Body Site
Cho, E., ROSNER, B. A., & Colditz, G. A. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0632 · Cited by 214
Research works printed but not linked: 1
- DeNavas‐Walt C, 2006, Income, poverty, and health insurance coverage in the United States: 2005. US Census Bureau, Current Population Reports, P60‐231
Cited by
Sorted by citations
Projections of the cost of cancer care in the United States: 2010–2020
Mariotto, A. B., Robin Yabroff, K., Shao, Y., Feuer, E. J., & Brown, M. L. (2011) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq495 · Cited by 2,657
US Health Care Spending by Payer and Health Condition, 1996-2016
Dieleman, J. L., Cao, J., Chapin, A., Chen, C., Li, Z., Liu, A., Horst, C., Kaldjian, A., Matyasz, T., Scott, K. W., et al. (2020) · JAMA · doi:10.1001/jama.2020.0734 · Cited by 1,313
Financial Hardships Experienced by Cancer Survivors: A Systematic Review
Altice, C. K., Banegas, M. P., Tucker-Seeley, R. D., & Yabroff, K. R. (2017) · Journal of the National Cancer Institute · doi:10.1093/jnci/djw205 · Cited by 864
Integration of oncology and palliative care: a Lancet Oncology Commission
Kaasa, S., Loge, J. H., Aapro, M., Albreht, T., Anderson, R., Bruera, E. D., Brunelli, C., Caraceni, A. T., Cervantes, A. M. R., Currow, D. C., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30415-7 · Cited by 879
Delivering affordable cancer care in high-income countries
Sullivan, R., Peppercorn, J., Sikora, K., Zalcberg, J., Meropol, N. J., Amir, E., Khayat, D., Boyle, P., Autier, P., Tannock, I. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(11)70141-3 · Cited by 718
Metadata
- Authors
- Tangka, F. K., Trogdon, J. G., Richardson, L. C., Howard, D., Sabatino, S. A., & Finkelstein, E. A.
- Affiliations
- Centers for Disease Control and Prevention (US)
- RTI International (US)
- Emory University (US)
- National University of Singapore (SG)
- Corresponding author
- Tangka, Florence K.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-05-10
- Volume
- 116
- Issue
- 14
- Pages
- 3477-3484
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1590770963
- Cited by
- 156
- References
- 22
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 5 · 2022: 7 · 2021: 11 · 2020: 15 · 2019: 10 · 2018: 9 · 2017: 8 · 2016: 12 · 2015: 11 · 2014: 11 · 2013: 16 · 2012: 14
- FWCI
- 39.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer (publishedVersion, public-domain)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- cancer treatment costs, health care costs, cost trends, Medicare, Medicaid, private insurance, out-of-pocket costs, hospitalization, outpatient care, cancer prevalence, United States
- MeSH terms
- Financing, Government, Financing, Personal, Medicare, Humans, Inpatients, Insurance, Health, Medicaid, Neoplasms, Outpatients, United States, Prevalence, Drug Costs, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review